Cat. No. 5310
Chemical Name: N2-[2-Methoxy-4-[4-(4-methyl-1-pipe
Biological ActivityPotent anaplastic lymphoma kinase (ALK) inhibitor (IC50 = 3.5 nM). Also inhibits Ack and ROS1 activity (IC50 values are 5.8 and 8.9 nM respectively). Attenuates proliferation, and induces apoptosis of NPM-ALK+ T cell anaplastic large-cell lymphoma (ALCL) cells in vitro. Suppresses tumor growth of NPM-ALK+ ALCL cell xenografts in mice. Causes tumor shrinkage in hEML4-ALK transgenic mice. Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Awad and Shaw (2014) ALK Inhibitors in Non-Small Cell Lung Cancer: Crizotinib and Beyond. Clin.Adv.Hematol.Oncol. 12 429. PMID: 25322323.
George et al (2014) The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget 5 5750. PMID: 25026277.
Mori et al (2014) The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol.Cancer Ther. 13 329. PMID: 24419060.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses ASP 3026 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: ASP 3026, supplier, ASP3026, potent, alk, inhibitors, inhibits, anaplastic, lymphoma, kinases, tyrosine, ack, ros1, crizotinib, npm-alk, non-small, cell, lung, cancer, antitumor, TNK2, tyrosine, kinase, non-receptor, 2, Tocris Bioscience, ALK Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective TrkB receptor agonist; neuroprotectantAV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinasesCP 724714
Potent and selective ErbB2 inhibitorMitoglitazone
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitorCHMFL-FLT3-122
Potent and selective FLT3 inhibitor
October 30 - November 3, 2016
Boston, MA, USA